""What this shows us is that there's scalability to this treatment to a broad population showing that we can achieve mild or less tricuspid regurgitation in virtually all patients, and that this significantly improves patients' quality of life by all objective and subjective metrics.""
""We demonstrated that we have a technology that can be applied to a larger population beyond those studied in the clinical trials.""
Patients with severe symptomatic tricuspid regurgitation experienced significant improvements in cardiovascular health and quality of life within 30 days after nonsurgical tricuspid valve replacement. The procedure is effective and safe, demonstrating scalability to a broader population. It can achieve mild or less tricuspid regurgitation in nearly all patients, enhancing quality of life by various metrics. Tricuspid regurgitation is the most common valvular heart disease in older adults, previously underrecognized and inadequately treated. The FDA approved this procedure in February 2024 as an alternative treatment option.
#tricuspid-valve-replacement #heart-valve-disease #cardiovascular-health #tricuspid-regurgitation #fda-approval
Read at News Center
Unable to calculate read time
Collection
[
|
...
]